Chemokine and chemokine receptor structure and interactions: Implications for therapeutic strategies

Immunology and Cell Biology

Volumn 93, Issue 4, 2015, Pages 372-383

  Kufareva, Irina ^a   Salanga, Catherina L ^a   Handel, Tracy M ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; G PROTEIN COUPLED RECEPTOR; GLYCOPROTEIN GP 120; MARAVIROC; MICROBICIDE; MULTIPROTEIN COMPLEX; PROTEIN VARIANT; RANTES; VIRUS FUSION PROTEIN; GLYCOSAMINOGLYCAN;

ANTIVIRAL ACTIVITY; BINDING SITE; CHIMERA; DRUG PROTEIN BINDING; DRUG STRUCTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MOLECULAR MODEL; OLIGOMERIZATION; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN POLYMERIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; ANIMAL; CELL MOTION; METABOLISM; MOLECULARLY TARGETED THERAPY; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELL MOVEMENT; CHEMOKINES; GLYCOSAMINOGLYCANS; HUMANS; MOLECULAR TARGETED THERAPY; MULTIPROTEIN COMPLEXES; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; RECEPTORS, CHEMOKINE; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84928208186     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2015.15     Document Type: Review

References (108)

1. Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol 2014; 32: 659-702.
2. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998; 392: 565-568.
3. Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol 2001; 2: 108-115.
4. Salanga CL, Handel TM. Chemokine oligomerization and interactions with receptors and glycosaminoglycans: the role of structural dynamics in function. Exp Cell Res 2011; 317: 590-601.
5. Scholten DJ, Canals M, Maussang D, Roumen L, Smit MJ, Wijtmans M et al. Pharmacological modulation of chemokine receptor function. Br J Pharmacol 2011; 165: 1617-1643.
6. Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ et al. International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev 2014; 66: 1-79.
7. Clore GM, Appella E, Yamada M, Matsushima K, Gronenborn AM. Three-dimensional structure of interleukin 8 in solution. Biochemistry 1990; 29: 1689-1696.
8. Lodi PJ, Garrett DS, Kuszewski J, Tsang ML, Weatherbee JA, Leonard WJ et al. Highresolution solution structure of the beta chemokine hMIP-1 beta by multidimensional NMR. Science 1994; 263: 1762-1767.
9. Skelton NJ, Aspiras F, Ogez J, Schall TJ. Proton NMR assignments and solution conformation of RANTES, a chemokine of the C-C type. Biochemistry 1995; 34: 5329-5342.
10. Handel TM, Domaille PJ. Heteronuclear (1H, 13C, 15 N) NMR assignments and solution structure of the monocyte chemoattractant protein-1 (MCP-1) dimer. Biochemistry 1996; 35: 6569-6584.
11. Mizoue LS, Bazan JF, Johnson EC, Handel TM. Solution structure and dynamics of the CX3C chemokine domain of fractalkine and its interaction with an N-terminal fragment of CX3CR1. Biochemistry 1999; 38: 1402-1414.
12. Hoover DM, Mizoue LS, Handel TM, Lubkowski J. The crystal structure of the chemokine domain of fractalkine shows a novel quaternary arrangement. J Biol Chem 2000; 275: 23187-23193.
13. Tuinstra RL, Peterson FC, Kutlesa S, Elgin ES, Kron M. A, Volkman BF. Interconversion between two unrelated protein folds in the lymphotactin native state. Proc Natl Acad Sci USA 2008; 105: 5057-5062.
14. Rajarathnam K, Sykes B, Kay C, Dewald B, Geiser T, Baggiolini M et al. Neutrophil activation by monomeric interleukin-8. Science 1994; 264: 90-92.
15. Paavola CD, Hemmerich S, Grunberger D, Polsky I, Bloom A, Freedman R et al. Monomeric monocyte chemoattractant Protein-1 (MCP-1) binds and activates the MCP-1 receptor CCR2B. J Biol Chem 1998; 273: 33157-33165.
16. Wang X, Sharp JS, Handel TM, Prestegard JH. Chemokine oligomerization in cell signaling and migration. Prog Mol Biol Transl Sci 2013; 117: 531-578.
17. Ren M, Guo Q, Guo L, Lenz M, Qian F, Koenen RR et al. Polymerization of MIP-1 chemokine (CCL3 and CCL4) and clearance of MIP-1 by insulin-degrading enzyme. EMBO J 2010; 29: 3952-3966.
18. Wang X, Watson C, Sharp JS, Handel TM, Prestegard JH. Oligomeric structure of the chemokine CCL5/RANTES from NMR, MS, and SAXS data. Structure 2011; 19: 1138-1148.
19. Proudfoot AE, Handel TM, Johnson Z, Lau EK, LiWang P, Clark-Lewis I et al. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci USA 2003; 100: 1885-1890.
20. Campanella GS, Grimm J, Manice LA, Colvin RA, Medoff BD, Wojtkiewicz GR et al. Oligomerization of CXCL10 is necessary for endothelial cell presentation and in vivo activity. J Immunol 2006; 177: 6991-6998.
21. Rot A. Neutrophil attractant/activation protein-1 (interleukin-8) induces in vitro neutrophil migration by haptotactic mechanism. Eur J Immunol 1993; 23: 303-306.
22. Haessler U, Pisano M, Wu M, Swartz M. A. Dendritic cell chemotaxis in 3D under defined chemokine gradients reveals differential response to ligands CCL21 and CCL19. Proc Natl Acad Sci USA 2011; 108: 5614-5619.
23. Weber M, Hauschild R, Schwarz J, Moussion C, de Vries I, Legler DF et al. Interstitial dendritic cell guidance by haptotactic chemokine gradients. Science 2013; 339: 328-332.
24. Ali S, Robertson H, Wain JH, Isaacs JD, Malik G, Kirby JA. A non-glycosaminoglycanbinding variant of CC chemokine ligand 7 (monocyte chemoattractant protein-3) antagonizes chemokine-mediated inflammation. J Immunol 2005; 175: 1257-1266.
25. Dubrac A, Quemener C, Lacazette E, Lopez F, Zanibellato C, Wu WG et al. Functional divergence between 2 chemokines is conferred by single amino acid change. Blood 2010; 116: 4703-4711.
26. Lebel-Haziv Y, Meshel T, Soria G, Yeheskel A, Mamon E, Ben-Baruch A. Breast cancer: coordinated regulation of CCL2 secretion by intracellular glycosaminoglycans and chemokine motifs. Neoplasia 2014; 16: 723-740.
27. Middleton J, Neil S, Wintle J, Clark-Lewis I, Moore H, Lam C et al. Transcytosis and surface presentation of IL-8 by venular endothelial cells. Cell 1997; 91: 385-395.
28. Wang L, Fuster M, Sriramarao P, Esko JD. Endothelial heparan sulfate deficiency impairs L-selectin-and chemokine-mediated neutrophil trafficking during inflammatory responses. Nat Immunol 2005; 6: 902-910.
29. Ellyard JI, Simson L, Bezos A, Johnston K, Freeman C, Parish CR. Eotaxin selectively binds heparin. An interaction that protects eotaxin from proteolysis and potentiates chemotactic activity in vivo. J Biol Chem 2007; 282: 15238-15247.
30. Roscic-Mrkic B, Fischer M, Leemann C, Manrique A, Gordon CJ, Moore JP et al. RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement. Blood 2003; 102: 1169-1177.
31. Hoogewerf AJ, Kuschert GS, Proudfoot AE, Borlat F, Clark-Lewis I, Power CA et al. Glycosaminoglycans mediate cell surface oligomerization of chemokines. Biochemistry 1997; 36: 13570-13578.
32. Lau EK, Paavola CD, Johnson Z, Gaudry JP, Geretti E, Borlat F et al. Identification of the glycosaminoglycan binding site of the CC chemokine, MCP-1: implications for structure and function in vivo. J Biol Chem 2004; 279: 22294-22305.
33. Kuschert GS, Coulin F, Power CA, Proudfoot AE, Hubbard RE, Hoogewerf AJ et al. Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemistry 1999; 38: 12959-12968.
34. Crown SE, Yu Y, Sweeney MD, Leary JA, Handel TM. Heterodimerization of CCR2 chemokines and regulation by glycosaminoglycan binding. J Biol Chem 2006; 281: 25438-25446.
35. Johnson Z, Kosco-Vilbois MH, Herren S, Cirillo R, Muzio V, Zaratin P et al. Interference with heparin binding and oligomerization creates a novel antiinflammatory strategy targeting the chemokine system. J Immunol 2004; 173: 5776-5785.
36. Braunersreuther V, Steffens S, Arnaud C, Pelli G, Burger F, Proudfoot A et al. A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice. Arterioscler Thromb Vasc Biol 2008; 28: 1090-1096.
37. Braunersreuther V, Pellieux C, Pelli G, Burger F, Steffens S, Montessuit C et al. Chemokine CCL5/RANTES inhibition reduces myocardial reperfusion injury in atherosclerotic mice. J Mol Cell Cardiol 2010; 48: 789-798.
38. Berres ML, Koenen RR, Rueland A, Zaldivar MM, Heinrichs D, Sahin H et al. Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. J Clin Invest 2010; 120: 4129-4140.
39. O'Boyle G, Mellor P, Kirby JA, Ali S. Anti-inflammatory therapy by intravenous delivery of non-heparan sulfate-binding CXCL12. FASEB J 2009; 23: 3906-3916.
40. Handel TM, Johnson Z, Rodrigues DH, Dos Santos AC, Cirillo R, Muzio V et al. An engineered monomer of CCL2 has anti-inflammatory properties emphasizing the importance of oligomerization for chemokine activity in vivo. J Leukoc Biol 2008; 84: 1101-1108.
41. Shahrara S, Proudfoot AE, Park CC, Volin MV, Haines GK, Woods JM et al. Inhibition of monocyte chemoattractant protein-1 ameliorates rat adjuvant-induced arthritis. J Immunol 2008; 180: 3447-3456.
42. Thiele S, Rosenkilde MM. Interaction of chemokines with their receptors-from initial chemokine binding to receptor activating steps. Curr Med Chem 2014; 21: 3594-3614.
43. Shaw JP, Johnson Z, Borlat F, Zwahlen C, Kungl A, Roulin K et al. The X-ray structure of RANTES: heparin-derived disaccharides allows the rational design of chemokine inhibitors. Structure 2004; 12: 2081-2093.
44. Murphy JW, Cho Y, Sachpatzidis A, Fan C, Hodsdon ME, Lolis E. Structural and functional basis of CXCL12 (stromal cell-derived factor-1 alpha) binding to heparin. J Biol Chem 2007; 282: 10018-10027.
45. Salanga CL, Dyer DP, Kiselar JG, Gupta S, Chance MR, Handel TM. Multiple glycosaminoglycan-binding epitopes of monocyte chemoattractant protein-3/CCL7 enable it to function as a non-oligomerizing chemokine. J Biol Chem 2014; 289: 14896-14912.
46. Ziarek JJ, Veldkamp CT, Zhang F, Murray NJ, Kartz GA, Liang X et al. Heparin oligosaccharides inhibit chemokine (CXC Motif) ligand 12 (CXCL12) cardioprotection by binding orthogonal to the dimerization interface, promoting oligomerization, and competing with the chemokine (CXC Motif) receptor 4 (CXCR4) N terminus. J Biol Chem 2013; 288: 737-746.
47. Stringer SE, Forster MJ, Mulloy B, Bishop CR, Graham GJ, Gallagher JT. Characterization of the binding site on heparan sulfate for macrophage inflammatory protein 1alpha. Blood 2002; 100: 1543-1550.
48. Clark-Lewis I, Schumacher C, Baggiolini M, Moser B. Structure-activity relationships of interleukin-8 determined using chemically synthesized analogs. Critical role of NH2-terminal residues and evidence for uncoupling of neutrophil chemotaxis, exocytosis, and receptor binding activities. J Biol Chem 1991; 266: 23128-23134.
49. Moser B, Dewald B, Barella L, Schumacher C, Baggiolini M, Clark-Lewis I. Interleukin-8 antagonists generated by N-terminal modification. J Biol Chem 1993; 268: 7125-7128.
50. Clark-Lewis I, Kim KS, Rajarathnam K, Gong JH, Dewald B, Moser B et al. Structureactivity relationships of chemokines. J Leukoc Biol 1995; 57: 703-711.
51. Moelants EA, Mortier A, Van Damme J, Proost P. In vivo regulation of chemokine activity by post-translational modification. Immunol Cell Biol 2013; 91: 402-407.
52. Pease JE, Wang J, Ponath PD, Murphy PM. The N-terminal extracellular segments of the chemokine receptors CCR1 and CCR3 are determinants for MIP-1alpha and eotaxin binding, respectively, but a second domain is essential for efficient receptor activation. J Biol Chem 1998; 273: 19972-19976.
53. Monteclaro FS, Charo IF. The amino-terminal domain of CCR2 is both necessary and sufficient for high affinity binding of monocyte chemoattractant protein 1: receptor activation by a pseudo-tethered ligand. J Biol Chem 1997; 272: 23186-23190.
54. Monteclaro FS, Charo IF. The amino-terminal extracellular domain of the MCP-1 receptor, but not the RANTES/MIP-1a receptor, confers chemokine selectivity: evidence for a two-step mechanism fir MCP-1 receptor activation. J Biol Chem 1996; 271: 19084-19092.
55. Kofuku Y, Yoshiura C, Ueda T, Terasawa H, Hirai T, Tominaga S et al. Structural basis of the interaction between chemokine stromal cell-derived factor-1/CXCL12 and its G-protein-coupled receptor CXCR4. J Biol Chem 2009; 284: 35240-35250.
56. Gerlach LO, Skerlj RT, Bridger GJ, Schwartz TW. Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J Biol Chem 2001; 276: 14153-14160.
57. Gong JH, Ratkay LG, Waterfield JD, Clark-Lewis I. An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. J Exp Med 1997; 186: 131-137.
58. Matoba T, Egashira K. Anti-inflammatory gene therapy for cardiovascular disease. Curr Gene Ther 2011; 11: 442-446.
59. Tsuruta S, Nakamuta M, Enjoji M, Kotoh K, Hiasa K, Egashira K et al. Anti-monocyte chemoattractant protein-1 gene therapy prevents dimethylnitrosamine-induced hepatic fibrosis in rats. Int J Mol Med 2004; 14: 837-842.
60. Plater-Zyberk C, Hoogewerf AJ, Proudfoot AE, Power CA, Wells TN. Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice. Immunol Lett 1997; 57: 117-120.
61. Veillard NR, Kwak B, Pelli G, Mulhaupt F, James RW, Proudfoot AE et al. Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res 2004; 94: 253-261.
62. Matsui M, Weaver J, Proudfoot AE, Wujek JR, Wei T, Richer E et al. Treatment of experimental autoimmune encephalomyelitis with the chemokine receptor antagonist Met-RANTES. J Neuroimmunol 2002; 128: 16-22.
63. Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AE, Balkwill FR. A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res 2003; 63: 8360-8365.
64. Adage T, Piccinini AM, Falsone A, Trinker M, Robinson J, Gesslbauer B et al. Structure-based design of decoy chemokines as a way to explore the pharmacological potential of glycosaminoglycans. Br J Pharmacol 2012; 167: 1195-1205.
65. Simmons G, Clapham PR, Picard L, Offord RE, Rosenkilde MM, Schwartz TW et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997; 276: 276-279.
66. Lederman MM, Veazey RS, Offord R, Mosier DE, Dufour J, Mefford M et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 2004; 306: 485-487.
67. Pastore C, Picchio GR, Galimi F, Fish R, Hartley O, Offord RE et al. Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES. Antimicrob Agents Chemother 2003; 47: 509-517.
68. Gaertner H, Cerini F, Escola J-M, Kuenzi G, Melotti A, Offord R et al. Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide. Proc Natl Acad Sci USA 2008; 105: 17706-17711.
69. Veazey RS, Ling B, Green LC, Ribka EP, Lifson JD, Piatak M Jr et al. Topically applied recombinant chemokine analogues fully protect macaques from vaginal simian-human immunodeficiency virus challenge. J Infect Dis 2009; 199: 1525-1527.
70. Colin P, Benureau Y, Staropoli I, Wang Y, Gonzalez N, Alcami J et al. HIV-1 exploits CCR5 conformational heterogeneity to escape inhibition by chemokines. Proc Natl Acad Sci USA 2013; 110: 9475-9480.
71. Castaldo C, Benicchi T, Otrocka M, Mori E, Pilli E, Ferruzzi P et al. CXCR4 antagonists: a screening strategy for identification of functionally selective ligands. J Biomol Screen 2014; 19: 859-869.
72. Wang NX, Sieg SF, Lederman MM, Offord RE, Hartley O, von Recum HA. Using glycosaminoglycan/chemokine interactions for the long-term delivery of 5P12-RANTES in HIV prevention. Mol Pharm 2013; 10: 3564-3573.
73. Eckert DM, Kim PS. Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 2001; 70: 777-810.
74. Zhao B, Mankowski MK, Snyder BA, Ptak RG, Liwang PJ. Highly potent chimeric inhibitors targeting two steps of HIV cell entry. J Biol Chem 2011; 286: 28370-28381.
75. Stephens B, Handel TM. Chemokine receptor oligomerization and allostery. Prog Mol Biol Transl Sci 2013; 115: 375-420.
76. Martinez-Munoz L, Barroso R, Dyrhaug SY, Navarro G, Lucas P, Soriano SF et al. CCR5/CD4/CXCR4 oligomerization prevents HIV-1 gp120IIIB binding to the cell surface. Proc Natl Acad Sci USA 2014; 111: E1960-E1969.
77. Millard CJ, Ludeman JP, Canals M, Bridgford JL, Hinds MG, Clayton DJ et al. Structural basis of receptor sulfotyrosine recognition by a CC chemokine: the N-terminal region of CCR3 bound to CCL11/Eotaxin-1. Structure 2014; 22: 1571-1581.
78. Veldkamp CT, Seibert C, Peterson FC, De la Cruz NB, Haugner JC III, Basnet H et al. Structural basis of CXCR4 sulfotyrosine recognition by the chemokine SDF-1/CXCL12. Sci Signal 2008; 1: ra4.
79. Skelton NJ, Quan C, Reilly D, Lowman H. Structure of a CXC chemokine-receptor fragment in complex with interleukin-8. Structure 1999; 7: 157-168.
80. Kufareva I, Stephens BS, Holden LG, Qin L, Zhao C, Kawamura T et al. Stoichiometry and geometry of the CXC chemokine receptor 4 complex with CXC ligand 12: molecular modeling and experimental validation. Proc Natl Acad Sci USA 2014; 111: E5363-E5372.
81. Nasser MW, Raghuwanshi SK, Grant DJ, Jala VR, Rajarathnam K, Richardson RM. Differential activation and regulation of CXCR1 and CXCR2 by CXCL8 monomer and dimer. J Immunol 2009; 183: 3425-3432.
82. Qin L, Kufareva I, Holden LG, Wang C, Zheng Y, Zhao C et al. Crystal structure of the chemokine receptor CXCR4 in complex with a viral chemokine. Science (e-pub ahead of print 22 January 2015).
83. Takekoshi T, Ziarek JJ, Volkman BF, Hwang ST. A locked, dimeric CXCL12 variant effectively inhibits pulmonary metastasis of CXCR4-expressing melanoma cells due to enhanced serum stability. Mol Cancer Ther 2012; 11: 2516-2525.
84. Smith EW, Liu Y, Getschman AE, Peterson FC, Ziarek JJ, Li R et al. Structural analysis of a novel small molecule ligand bound to the CXCL12 chemokine. J Med Chem 2014; 57: 9693-9699.
85. Rosenbaum DM, Cherezov V, Hanson M. A, Rasmussen SGF, Thian FS, Kobilka TS et al. GPCR engineering yields high-resolution structural insights into 2-adrenergic receptor function. Science 2007; 318: 1266-1273.
86. Cherezov V, Rosenbaum DM, Hanson M. A, Rasmussen SGF, Thian FS, Kobilka TS et al. High-resolution crystal structure of an engineered human 2-adrenergic G protein coupled receptor. Science 2007; 318: 1258-1265.
87. Wu B, Chien EYT, Mol CD, Fenalti G, Liu W, Katritch V et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 2010; 330: 1066-1071.
88. Whorton MR, Jastrzebska B, PS-H Park, Fotiadis D, Engel A, Palczewski K et al. Efficient coupling of transducin to monomeric rhodopsin in a phospholipid bilayer. J Biol Chem 2008; 283: 4387-4394.
89. Bayburt TH, Vishnivetskiy SA, McLean M. A, Morizumi T, Huang C-C, JJG Tesmer et al. Monomeric rhodopsin is sufficient for normal rhodopsin kinase (GRK1) phosphorylation and Arrestin-1 binding. J Biol Chem 2011; 286: 1420-1428.
90. Tan Q, Zhu Y, Li J, Chen Z, Han GW, Kufareva I et al. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science 2013; 341: 1387-1390.
91. Garcia-Perez J, Rueda P, Alcami J, Rognan D, Arenzana-Seisdedos F, Lagane B et al. Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5). J Biol Chem 2011; 286: 33409-33421.
92. Muniz-Medina VM, Jones S, Maglich JM, Galardi C, Hollingsworth RE, Kazmierski WM et al. The relative activity of 'function sparing' HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property? Mol Pharmacol 2009; 75: 490-501.
93. Lagane B, Garcia-Perez J, Kellenberger E. Modeling the allosteric modulation of CCR5 function by Maraviroc. Drug Discov Today Technol 2013; 10: e297-e305.
94. Nijmeijer S, Leurs R, Smit MJ, Vischer HF. The Epstein-Barr virus-encoded G proteincoupled receptor BILF1 hetero-oligomerizes with human CXCR4, scavenges Gαi proteins, and constitutively impairs CXCR4 functioning. J Biol Chem 2010; 285: 29632-29641.
95. Farzan M, Mirzabekov T, Kolchinsky P, Wyatt R, Cayabyab M, Gerard NP et al. Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell 1999; 96: 667-676.
96. Kwon YD, Finzi A, Wu X, Dogo-Isonagie C, Lee LK, Moore LR et al. Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proc Natl Acad Sci USA 2012; 109: 5663-5668.
97. Julien J-P, Cupo A, Sok D, Stanfield RL, Lyumkis D, Deller MC et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013; 342: 1477-1483.
98. Pancera M, Majeed S, Ban Y-EA, Chen L, Huang C-C, Kong L et al. Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc Natl Acad Sci USA 2010; 107: 1166-1171.
99. Huang C-C, Lam SN, Acharya P, Tang M, Xiang S-H, Hussan SS-U et al. Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 2007; 317: 1930-1934.
100. Cormier EG, Tran DNH, Yukhayeva L, Olson WC, Dragic T. Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes. J Virol 2001; 75: 5541-5549.
101. Rizzuto CD, Wyatt R, Hernández-Ramos N, Sun Y, Kwong PD, Hendrickson WA et al. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 1998; 280: 1949-1953.
102. Rizzuto C, Sodroski J. Short communication: fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120. AIDS Res Hum Retroviruses 2000; 16: 741-749.
103. Dragic T. An overview of the determinants of CCR5 and CXCR4 co-receptor function. J Gen Virol 2001; 82: 1807-1814.
104. Tamamis P, Floudas Christodoulos A. Molecular recognition of CXCR4 by a dual tropic HIV-1 gp120 V3 loop. Biophys J 2013; 105: 1502-1514.
105. Tamamis P, Floudas CA. Molecular recognition of CCR5 by an HIV-1 gp120 V3 loop. PLoS One 2014; 9: e95767.
106. Verrier F, Borman AM, Brand D, Girard M. Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage. AIDS Res Hum Retroviruses 1999; 15: 731-743.
107. Jensen M. A, van 't Wout AB. Predicting HIV-1 coreceptor usage with sequence analysis. AIDS Rev 2003; 5: 104-112.
108. Carlson J, Baxter SA, Dreau D, Nesmelova IV. The heterodimerization of plateletderived chemokines. Biochim Biophys Acta 2013; 1834: 158-168.